+ Follow HALAVEN Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 885277
[Title] => Sponges and humans... alike in many ways
[Summary] => In November 2010, a new drug for cancer named Halaven (generic name eribulin mesylate) was approved by the US FDA (Food and Drug Administration).
[DatePublished] => 2012-12-13 00:00:00
[ColumnID] => 135735
[Focus] => 0
[AuthorID] => 1339989
[AuthorName] => Gisela Padilla-Concepcion, PhD
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 740509
[Title] => Breast cancer: Progress & promise in 2011
[Summary] => The field of breast cancer has been a model for innovation and discovery.
[DatePublished] => 2011-10-25 00:00:00
[ColumnID] => 133436
[Focus] => 0
[AuthorID] => 1778504
[AuthorName] => Tyrone M. Reyes M.D.
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] => http://img714.imageshack.us/img714/6105/lif1thumba.jpg
)
)
)
HALAVEN
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 885277
[Title] => Sponges and humans... alike in many ways
[Summary] => In November 2010, a new drug for cancer named Halaven (generic name eribulin mesylate) was approved by the US FDA (Food and Drug Administration).
[DatePublished] => 2012-12-13 00:00:00
[ColumnID] => 135735
[Focus] => 0
[AuthorID] => 1339989
[AuthorName] => Gisela Padilla-Concepcion, PhD
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 740509
[Title] => Breast cancer: Progress & promise in 2011
[Summary] => The field of breast cancer has been a model for innovation and discovery.
[DatePublished] => 2011-10-25 00:00:00
[ColumnID] => 133436
[Focus] => 0
[AuthorID] => 1778504
[AuthorName] => Tyrone M. Reyes M.D.
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] => http://img714.imageshack.us/img714/6105/lif1thumba.jpg
)
)
)
abtest
